SHIM
JAZZ icon

Stone House Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Stone House Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$241 Hold
1
– – ﹤0.01% 1168
2026
Q1 		$189 Buy
+1
New +$175 ﹤0.01% 949

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Stone House Investment Management's JAZZ Position: Q2 2026 in Review

Stone House Investment Management held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 1 share worth $241. The position accounts for ﹤0.01% of the portfolio, ranked #1168.

Stone House Investment Management first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Stone House Investment Management held 1 share of Jazz Pharmaceuticals worth $241 as of Q2 2026.
  • Stone House Investment Management left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1168 holding.
  • Stone House Investment Management first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.